ZAP Surgical Announces First ZAP-X Gyroscopic Radiosurgery Program Coming to Mexico at Gray Medical Institute
SAN CARLOS, Calif.--(BUSINESS WIRE)-- ZAP Surgical Systems, Inc., a global leader in non-invasive robotic brain surgery, today announced that its first ZAP-X® Gyroscopic Radiosurgery® platform will soon be installed in Mexico at the newly established Gray Medical Institute, located in San Pedro, part of the Monterrey Metropolitan area in the Mexican state of Nuevo León.
As a newly established outpatient institute, Gray Medical is transforming the landscape of cancer care in Mexico. Purpose-built to deliver comprehensive, end-to-end oncology services, the center integrates imaging, diagnostics, radiosurgery, infusion therapy and more—all within a single, patient-centric facility. This streamlined outpatient model ensures convenient, coordinated care while significantly reducing the costs typically associated with large inpatient hospitals.
Gray Medical is set to become the region's leading destination for cancer treatment with the arrival of the ZAP-X system. Offering a non-invasive alternative to open surgery for many patients, ZAP-X delivers a highly precise treatment for brain tumors and other neurological conditions—without incisions or anesthesia—and is typically completed in a single, brief outpatient visit. Installation of the ZAP-X system is scheduled for the fourth quarter of 2025, following the center's opening this summer.
The medical team will be led by Dr. Erik Edmundo Pérez Ramos, one of Mexico's foremost radiation oncologists and a respected professor. Dr. Pérez will work in close collaboration with Dr. Fabiola Flores (Neurologist), as well as Alan Quiroga, PhD, and Edgar Quiroga, PhD.
'ZAP-X is enabling us to bring world-class radiosurgery out of the big hospitals and into the community,' said Dr. Erik Edmundo Pérez Ramos, Gray Medical's Director of Radiation Oncology. 'This not only improves accessibility and convenience for patients but also establishes a new benchmark for cancer care in Mexico.'
The ZAP-X platform represents a major leap forward in the field of stereotactic radiosurgery (SRS). Renowned for its dual-gantry design, the ZAP-X system uniquely utilizes gyroscopic mobility to direct radiosurgical beams from thousands of potential unique angles to accurately focus radiation on the intended tumor or target. This innovative method aims to improve patient outcomes by enhancing the ability to avoid critical structures like the brain stem, eyes and optic nerves. Additionally, the pioneering approach aims to reduce exposure to healthy brain tissue, thereby safeguarding patient cognitive function.
ZAP-X also stands out as the first and only vault-free SRS delivery system, doing away with the necessity for healthcare providers to construct expensive shielded radiation treatment rooms, as well as providing the flexibility to site the system in locations previously considered inconceivable. ZAP-X also utilizes a modern linear accelerator to eliminate legacy use of Cobalt-60.
'We are proud to bring the first ZAP-X system to Mexico, and expanding access to advanced radiosurgical care,' said John R. Adler, MD, ZAP Surgical founder and CEO, as well as Emeritus Dorothy & TK Chan Professor of Neurosurgery and Radiation Oncology at Stanford University. 'The collaboration underscores our shared vision of expanding precision SRS beyond the traditional hospital model and directly into the hands of forward-thinking outpatient centers like Gray Medical.'
For more information about ZAP Surgical and the ZAP-X system, visit www.zapsurgical.com.
About ZAP Surgical Systems, Inc.
ZAP Surgical Systems, Inc. designs and manufactures the ZAP-X® Gyroscopic Radiosurgery® platform. ZAP was founded in 2014 by Dr. John R. Adler, Emeritus Dorothy & TK Chan Professor of Neurosurgery and Radiation Oncology at Stanford University. Dr. Adler is also renowned as the inventor of the CyberKnife ® system and founder of Accuray, Inc. The ZAP-X platform incorporates a unique vault-free design that typically eliminates the need for costly shielded treatment rooms. ZAP-X also utilizes a modern linear accelerator to eliminate legacy use of Cobalt-60. Learn more at ZAP Surgical and follow us on LinkedIn.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
4 hours ago
- Business Wire
EMEREN GROUP INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Emeren Group Ltd.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed sale of Emeren Group Ltd. (NYSE: SOL) to Shurya Vitra Ltd. Under the terms of the proposed transaction, shareholders of Emeren Group will receive $0.20 in cash per ordinary share or $2.00 in cash per American Depositary Share. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit
Business Wire
4 hours ago
- Business Wire
COUCHBASE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Couchbase, Inc.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed sale of Couchbase, Inc. (NasdaqGS: BASE) to Haveli Investments. Under the terms of the proposed transaction, shareholders of Couchbase will receive $24.50 in cash for each share of Couchbase that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit
Business Wire
5 hours ago
- Business Wire
CCS Presents Four Peer-Reviewed Posters at American Diabetes Association's 85th Scientific Sessions
CHICAGO--(BUSINESS WIRE)-- CCS, a leading provider of clinical solutions and home-delivered medical supplies for those living with chronic conditions, will present four peer-reviewed posters at the American Diabetes Association's (ADA) 85th Scientific Sessions, which will take place June 20–23 in Chicago. These latest poster presentations illustrate CCS's focus on delivering evidence-based approaches to diabetes care management that ensure patients have the education and coaching they need to thrive and cost-effectively stay adherent while managing their chronic condition. "At CCS, we meet patients where they are — with empathy, education, and evidence-based support..." Share The ADA Scientific Sessions is a globally recognized conference dedicated to advancing the field of diabetes. This annual meeting serves as a critical forum for presenting cutting-edge research, innovation, and new evidence-based approaches to diabetes prevention, management, and care. Presentation Highlights from CCS at the ADA Scientific Sessions CCS's clinical strategy and innovation vice president, Coni Dennis, DNP, RN, and NE-BC, will present findings for all four accepted poster presentations at the ADA's 85th Scientific Sessions, and she shared this insight leading into the event: 'At CCS, we meet patients where they are — with empathy, education, and evidence-based support. These poster presentations reflect our commitment to improving health outcomes for people with diabetes by combining data-driven clinical insight with hands-on, compassionate care.' All poster presentations will take place at the conference on Sunday, June 22, from 12:30–1:30 p.m. CT in West Hall F1. The following are the four specific posters that CCS will be presenting: Presentation Title: Evaluating the Impact of Multichannel Diabetes Care Coaching and Education in Patients New to Continuous Glucose Monitoring Abstract Number: 534 Summary: This study, part of an ongoing randomized control trial (RCT), evaluated whether adults with diabetes newly starting a continuous glucose monitor (CGM) achieve better outcomes when they receive diabetes self-management education and support (DSMES) from a certified diabetes care and education specialist (CDCES), compared to using a CGM alone. Presentation Title: Examining the Impact of Continuous Glucose Monitoring Sourcing in Medicaid Patients — Adherence, Healthcare Costs, and Utilization Abstract Number: 1046 Summary: This study compared healthcare costs and utilization among Medicaid beneficiaries who received CGM supplies through a pharmacy or a durable medical equipment provider. Presentation Title: Healthcare Costs and Utilization Among Patients Eligible for Continuous Glucose Monitors — A Comparison of Users and Nonusers Abstract Number: 1049 Summary: This retrospective cohort study used claims data to compare glycemic control, healthcare utilization, and total cost of care over 12 months among individuals on bolus insulin who used CGMs versus those who did not. It also assessed the incidence of hypoglycemia and diabetic ketoacidosis (DKA). Presentation Title: Evaluating an Evidence-Based Quality Improvement Initiative for Food Insecurity Screening and Referral in Adults with Diabetes Initiating Continuous Glucose Monitor Therapy Abstract Number: 1143 Summary: This study assessed food insecurity (FI) among adults with diabetes initiating CGM therapy, comparing rates to national averages and examining glycemic outcomes between food-insecure and food-secure individuals. These posters will be made available on the American Diabetes Association's website after August 25. About CCS CCS is the strategic partner addressing America's most pressing healthcare challenges through intelligent chronic care management, tackling the $412 billion annual diabetes burden and chronic conditions affecting over 133 million Americans. At the core of CCS's differentiated model is LivingConnected®, a human-led, digitally enabled clinical solution. PropheSee™ — an AI-powered predictive model that identifies nonadherence risk and delivers personalized interventions — is an integral part of this solution, creating a first-of-its-kind platform to improve adherence, enhance clinical outcomes, and help prevent costly hospitalizations. By combining data-driven insights with three decades of industry relationships, CCS is the smart choice for health plans, providers, employers, and manufacturers who believe that value-based care starts by keeping patients healthy and delivers benefits like lower cost of care, improved HEDIS scores, and alleviating provider burnout. CCS's approach extends clinical reach while supporting over 200,000 people nationwide with home-delivered medical supplies and pharmaceuticals annually. Recognized as a Great Place to Work® and with numerous peer-reviewed publications validating our care management approach, CCS is more than a trusted supplier — we're a partner in transforming chronic care delivery. To learn more about how CCS is addressing today's healthcare challenges, visit or connect with us on LinkedIn.
